AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug

AbbVie received a Complete Response Letter (CRL) from the FDA regarding its wrinkle drug, trenibotulinumtoxinE (TrenibotE), citing manufacturing issues, not safety or efficacy concerns. The company plans to address the feedback promptly and submit a response in the coming months. Amidst this, AbbVie also announced a $1.4 billion investment for a new pharmaceutical manufacturing campus in North Carolina, focusing on advanced technologies for its immunology, neuroscience, and oncology medicines.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin